3
Announcements
Trials
Browse
Landscape
Status
Available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
108
Precursor Cell Lymphoblastic Leukemia-Lymphoma
41
Lymphoma, Non-Hodgkin
41
Lymphoma, Mantle-Cell
32
Recurrence
31
Lymphoma, Large B-Cell, Diffuse
27
Leukemia, Myeloid, Acute
25
Neoplasms
24
Lymphoma, Follicular
22
Leukemia
22
Lymphoma
21
Lymphoma, B-Cell, Marginal Zone
18
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
17
Burkitt Lymphoma
16
Lymphoma, B-Cell
11
Hematologic Neoplasms
11
Waldenstrom Macroglobulinemia
9
Multiple Myeloma
9
Myelodysplastic Syndromes
8
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
7
Leukemia, Biphenotypic, Acute
7
Chromosome 17 deletion
6
Leukemia, B-Cell
5
Leukemia, Myelomonocytic, Chronic
4
Neoplasm Metastasis
3
Lymphoproliferative Disorders
3
Lymphoma, T-Cell
3
Leukemia, Prolymphocytic, T-Cell
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Prostatic Neoplasms
2
Interventions
fludarabine phosphate
7
Whole-Body Irradiation
7
Cyclophosphamide
7
fludarabine
6
Mycophenolic Acid
6
Tacrolimus
3
Peripheral Blood Stem Cell Transplantation
3
Sirolimus
2
Cyclosporine
2
Antilymphocyte Serum
2
Allopurinol
2
venetoclax
1
itacitinib
1
carmustine, poliferprosan 20 drug combination
1
Melphalan
1
Hematopoietic Stem Cell Transplantation
1
Etoposide
1
Cytarabine
1
Cyclosporins
1
Carmustine
1
Association
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Plasma Cell
×
venetoclax
×
Lymphoid
×
Clear all
NCT03123029
2026-01-30
Expanded Access to Venetoclax
AbbVie
Available